The Peptide Progress Independent peptide research guides

Compound research guide

Sermorelin: research, evidence and testing

Sermorelin is associated with the first 29 residues of human growth-hormone-releasing hormone, the segment responsible for much of its biological activity.

By The Peptide Progress Editorial TeamLast reviewed 19 September 2026Reading time 7 minutesCited sources 4

Evidence, not personal-use guidance

This page explains research terminology and documentation. It does not provide medical advice, dosing, injection, administration or a recommendation to obtain or use any substance.

What is Sermorelin?

Sermorelin is associated with the first 29 residues of human growth-hormone-releasing hormone, the segment responsible for much of its biological activity.

Search results often combine research papers, supplier descriptions and personal claims. Those sources answer different questions. A paper can describe a mechanism or study outcome; only a batch-specific analytical record can describe the tested sample.

Identity and naming

The sequence and terminal chemistry should be stated explicitly. “GRF(1-29)”, “sermorelin” and modified analogues are not interchangeable labels unless the structure is shown to match.

Useful records state the exact material, expected molecular characteristics, batch code, sample identifier and form. See peptide sequence and molecular weight for why a familiar name is not enough.

What the research base shows

The literature includes endocrine diagnostic and pharmacology work. Historical or jurisdiction-specific pharmaceutical use does not prove the quality, approval or suitability of a current research material.

Evidence should be sorted by level: biochemical or cell studies, animal models, observational human data, controlled trials and regulatory evidence. A result at one level should not be silently rewritten as a conclusion at another.

Analytical and COA questions

Check mass agreement, sequence-related impurities, peak integration and batch traceability. Closely related analogues make a nickname-only certificate particularly weak.

  • Does the report name this exact molecular form?
  • Does the sample or batch code match the container?
  • Are identity, peak-area purity and quantitative content reported separately?
  • Can the laboratory and report number be independently traced?

Use the field-by-field COA guide before relying on a headline percentage.

What this page cannot establish

It cannot establish that any commercial material is genuine, sterile, safe, legally supplied or suitable for a particular purpose. Regulatory status and authorised uses can change and vary by country; consult the MHRA Products registry and other relevant official sources.

Frequently asked questions

What is GRF(1-29)?

It refers to the N-terminal 29-residue fragment of growth-hormone-releasing factor. Exact form and modifications still need to be stated.

Is sermorelin the same as “CJC no DAC”?

The labels are used inconsistently online; exact sequence and substitutions must be compared.

Related external reading:

External links are editorial references, not endorsements.

Research sources

  1. PubMed literature search: Sermorelin.
  2. ClinicalTrials.gov search: Sermorelin.
  3. IUPAC peptide terminology.
  4. ICH Q2(R2): analytical procedure validation.

Search links are provided because the literature and regulatory status can change. Sources were checked on 19 September 2026.